Skip to main content
padlock icon - secure page this page is secure

Open Access Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy

Download Article:
 Download
(PDF 381.9 kb)
 
The research and development of smart radiodrugs is the goal of the Center of Radiopharmaceutical Science of ETH, PSI, and USZ. Positron Emission Tomography (PET) allows the non-invasive visualization of biochemical processes within the body. Radiolabeled PET-tracers allow the study of neurophysiological diseases like Alzheimer, Parkinson's disease or the imaging of metastatic tumors. PET-techniques are nowadays an important part of routine nuclear medicine diagnosis. Tumor-cell targeting biomolecules (e.g. antibodies or peptides) coupled to therapeutic radionuclides can sterilize the malignant cells while sparing healthy tissue. This so-called targeted radionuclide therapy has made tremendous progress in the recent years and the first approved radiotherapeutics are available for clinical use.

34 References.

No Supplementary Data.
No Article Media
No Metrics

Keywords: MOLECULAR IMAGING; PET-TRACER; RADIOIMMUNOTHERAPY; RADIONUCLIDE THERAPY; RADIOPHARMACEUTICALS

Document Type: Research Article

Publication date: October 1, 2004

More about this publication?
  • International Journal for Chemistry and Official Membership Journal of the Swiss Chemical Society (SCS) and its Divisions

    CHIMIA, a scientific journal for chemistry in the broadest sense, is published 10 times a year and covers the interests of a wide and diverse readership. Contributions from all fields of chemistry and related areas are considered for publication in the form of Review Articles and Notes. A characteristic feature of CHIMIA are the thematic issues, each devoted to an area of great current significance.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Information for Advertisers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more